BAT Subsidiary WITCO: Vuse Has Strong Positive Impact on Revenue

Regulations by 2FIRSTS.ai
Apr.24.2024
BAT Subsidiary WITCO: Vuse Has Strong Positive Impact on Revenue
WITCO CEO Raoul Glynn announced at a press conference that Vuse e-cigarettes will positively impact company revenue.

According to a report by Newsday on April 24th, Raoul Glynn, CEO of West Indies Tobacco Company Limited (WITCO), announced at a press conference held at the Queen's Hall in Spain on April 23rd that the e-cigarette brand Vuse will have a strong and positive impact on the company's revenue.

 

The quality of Vuse products surpasses that of other brands on the market, with attractive prices and a strong profit structure. Witco's advantage lies in its distribution and ability to obtain the necessary products, which is what we value.

 

Greene stated that approximately 12% of consumers in the market are using e-cigarette products. "We anticipated changes in the market and observed e-cigarettes growing in a way that does not decrease tobacco sales."

 

Last week, the company revealed that as of December 31, 2023, its annual revenue had increased by 5.9% compared to the previous year. The company's financial director, Johan Grosberg, stated that despite taking many measures to improve operational efficiency last year, increased costs of raw materials, packaging, and labor led to an increase in sales costs. However, they were able to benefit from reduced expenses.

 

The brand support expenses align with our marketing plan, allowing us to trim slightly and execute the plan more effectively. Additionally, as part of a large group, we benefit from some restructuring taking place outside of the group.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Singapore sentencing: 17,000+ vape pods seized; man convicted of multiple offences
Singapore sentencing: 17,000+ vape pods seized; man convicted of multiple offences
A 28-year-old man in Singapore was sentenced on Jan 22 after admitting to six offences spanning 2021 to 2024, including possessing vapes and vape pods for sale.
Jan.23 by 2FIRSTS.ai
U.S. FDA posts TPSAC meeting materials ahead of discussion on ZYN MRTP applications
U.S. FDA posts TPSAC meeting materials ahead of discussion on ZYN MRTP applications
On January 20, 2026, the U.S. Food and Drug Administration (FDA) posted meeting materials ahead of a virtual Tobacco Products Scientific Advisory Committee (TPSAC) meeting scheduled for January 22, 2026, to discuss modified risk tobacco product (MRTP) applications submitted by Swedish Match USA, Inc. for 20 ZYN nicotine pouch products.
Jan.21 by 2FIRSTS.ai
Arizona Moves to Tighten Vape Supply-Chain Enforcement, Targeting Illicit Products
Arizona Moves to Tighten Vape Supply-Chain Enforcement, Targeting Illicit Products
Arizona state Sen. Shawnna Bolick introduced SB 1397 to curb illicit vapes by tracing product origins, intercepting illegal shipments, and cracking down on retailers that violate state law. The proposal would require manufacturers to hold a state license to sell in Arizona, with fines up to $10,000 for unlicensed sales.
Jan.30 by 2FIRSTS.ai
U.S. Fifth Circuit judges question FDA’s claim it has no de facto ban on flavored refillable e-cigarettes
U.S. Fifth Circuit judges question FDA’s claim it has no de facto ban on flavored refillable e-cigarettes
Law360 reports that a Fifth Circuit panel expressed skepticism about the FDA’s claim that it has no de facto ban on flavored refillable e-cigarette products, noting that only six applications had been approved out of hundreds of thousands and that near-100% denials look like a ban.
Jan.07 by 2FIRSTS.ai
SICPA Secures Five-Year UK Vape Tax Stamp Contract
SICPA Secures Five-Year UK Vape Tax Stamp Contract
HM Revenue and Customs (HMRC) has awarded a five-year contract to Swiss technology company SICPA and Cartor Security Printers to implement the United Kingdom’s new vaping duty stamp and track-and-trace system, beginning in April 2026.
Market
Feb.24
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11